Myriad Pharmaceuticals restructures

Myriad Pharmaceuticals Inc. (NASDAQ:MYRX) restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company suspended further development of its HIV program and plans to seek partners for the compounds, including MPC-4326, an oral formulation of a viral maturation inhibitor that is in Phase II testing. The lead compound in Myriad's cancer pipeline is Azixa, a small molecule microtubule destabilizing apoptosis-inducer in Phase II testing for metastatic melanoma and recurrent glioblastoma multiforme. ...